Member since 2019
Weill Cornell Graduate School of Medical Sciences
Gary Koretzky, MD, PhD is Vice Provost for Academic Integration at Cornell University and a Professor of Medicine at Weill Cornell Medicine. Previously, he was the Francis C. Wood Professor of Medicine, Vice Chair and Chief Scientific Office of the Department of Medicine, Investigator and Director of the Signal Transduction Program of the Abramson Family Cancer Research Institute at the University of Pennsylvania.
Dr. Koretzky received his AB from Cornell University (’78) and obtained his MD and PhD (Immunology) degrees at the University of Pennsylvania (’84). Dr. Koretzky then pursued clinical training in Internal Medicine and Rheumatology at the University of California at San Francisco. He re-entered the laboratory as a postdoctoral fellow, examining the molecular events associated with T cell activation. Dr. Koretzky moved to the University of Iowa in 1991 where he continued his research examining the biochemistry and molecular biology of signal transduction in hematopoietic cells until he moved to the University of Pennsylvania in 1999.
Koretzky’s research aims to better understand the signal transduction events that occur following engagement of the T cell antigen receptor. He has been continuously funded by the National Institutes of Health since establishing his independent research group, as the laboratory has expanded its interests to study more globally the molecular events important for immune cell development, differentiation and function. Initial studies focused on the CD45 tyrosine phosphatase as a positive regulator of immunoreceptor signaling. This work led naturally to an examination of the key biochemical events that occur following receptor engagement. The Koretzky lab approach was to identify novel regulators of signal transduction following T cell receptor ligation with studies leading to the isolation, characterization, and molecular cloning of several adapter molecules, which are critical for integration of signaling pathways. The laboratory has identified 3 such molecules including SH2 domain-containing leukocyte protein of 76 kDa (SLP-76), adhesion and degranulation-promoting adapter protein (ADAP) and promyelocytic leukemia RARa-regulated adapter molecule-1 (PRAM-1). There are ongoing projects studying the role of each of these molecules not only in T cells but also in other hematopoietic cells. In addition to studies of these positive regulators of immune signaling, the Koretzky laboratory has also had a long standing interest in signals that interfere with activation events in T cells. This interest led to studies of FAS and FAS ligand and to the role of diacylglycerol kinases as terminators of lymphocyte activation.
Dr. Koretzky has published more than 200 research articles. He is a past President of the American Society of Clinical Investigation (2000) and Councilor of the Association of American Physicians (2008-2012), is a Fellow of the American Association for the Advancement of Science (2004), a member of the Institute of Medicine of the National Academies (2008), a Fellow of the American Academy of Arts & Sciences (2012) and serves as the Editor-in-Chief of Immunological Reviews (2002-present).
Member since 2023
Strasbourg University & Academic Hospitals, France
Dr. Laurent Arnaud is full a Professor of Rheumatology at Strasbourg University & Academic Hospitals, France. He obtained his medical degree and a PhD in immunology from Paris University. His main clinical interests focus on the care of patients with Systemic Lupus Erythematosus (SLE). He is leading a research group focusing on innovative strategies to study the epidemiology of autoimmune diseases, with a particular interest for the use of novel diagnostic and therapeutic digital strategies based on big data and Artificial Intelligence.
With his team at the French National Reference Center for Rare Autoimmune Diseases of Strasbourg (CRMR RESO), he has published more than 200 articles in the field of rare diseases. Professor Arnaud is currently the President of the European Lupus Society (SLEuro) and Disease Coordinator for Lupus and relapsing polychondritis of the European Reference Network for rare diseases ReCONNET. He is the curator of a twitter account (@Lupusreference) about lupus education, followed by more than 12k people.
Member since 2023
UMass Chan Medical School
Dr. Caricchio is the Myles J. McDonough Chair in Rheumatology and Chief of the Division of Rheumatology at UMass Chan Medical School. He earned his M.D. and completed his rheumatology fellowship at the Catholic University of the Sacred Heart, Rome, Italy. He completed two postdoctoral research fellowships at the University of North Carolina at Chapel Hill and the University of Pennsylvania, Philadelphia. After a decade of high impact research in systemic lupus erythematosus (SLE), he undertook additional clinical training in internal medicine and rheumatology at Temple University to fulfill his call as physician-scientist. While in training, he continued to lead a NIH-funded laboratory focused on investigating the pathogenesis of SLE.
Before moving to UMass Chan, he directed the Temple Lupus Program in Philadelphia and provided access to a specialized program and to numerous clinical trials to indigent patients in north Philadelphia, one of the poorest areas in USA. He has since established the UMass Lupus Center, providing the local community advanced lupus care and access to clinical trials.
Dr. Caricchio has made important contributions to our understanding of the pathogenesis of SLE and is considered among the leading investigators in his field. He published seminal papers in elucidating the role of cell death as stimulator in autoimmunity, the role of sex hormones in manipulating cell death, tissue damage and the immune response, and more recently, the role of the microbiome and bacterial infections in driving autoimmune severity. His laboratory has been supported by the NIH, Arthritis Foundation, Lupus Foundation, and the Lupus Research Alliance.
Dr. Caricchio has published in Immunity, Journal of Immunology, Nature and JAMA, in addition to authoring editorials, reviews and book chapters all focused on SLE. He has been active nationally with the American College of Rheumatology as well as the Lupus Foundation of America and the Lupus Research Alliance and served on the editorial board of Arthritis and Rheumatology and Arthritis, Research and Therapy. During the COVID-19 pandemic, he developed a strategic therapeutic approach for patients with COVID-19-induced cytokine storm and led international trials to prevent this lethal complication.
In his current position he is developing a number of specialized programs at UMass Chan, including the lupus program, early arthritis program and CTD-ILD program, where patients are offered innovative therapies and the opportunity to participate to breakthrough clinical trials and translational research. Dr. Caricchio continues to have an active research laboratory focused on infectious triggers of lupus and prevention of end-organ damage in lupus nephritis. He practices rheumatology, supervising rheumatology fellows and focusing on lupus comprehensive care.
Member since 2022
Genentech, A Member of the Roche Group
Dr. Andrew Chan is Senior Vice President of Research-Biology at Genentech, Inc (GNE) where he has overseen biological research in oncology, immunology, neuroscience, infectious diseases, and biotherapeutic discovery for over the past decade. He is an accomplished leader in target discovery, drug discovery, and drug development. In his role, he has governance responsibilities over both GNE’s research and clinical portfolio through Phase 2 proof-of-concept studies.
Dr. Chan is a leader in biotherapeutics and has authored key reviews for academic and biopharmaceutical communities integrating lessons learned about disease pathogenesis and mechanisms of therapy. He is also a leader in advocating and implementing precision medicine strategies through biomarker discovery and development. Dr. Chan’s laboratory focuses on how our immune systems protect us against foreign pathogens yet can cause autoimmune and inflammatory diseases. He has published over 100 research papers, review articles and books. Dr. Chan himself is a co-inventor of ocrelizumab (Ocrevus™), the first B-cell directed therapy approved by the FDA for treatment of both relapsing and progressive forms of multiple sclerosis.
Dr. Chan plays key roles to bridge academia, patient advocacy, and industry. He presently serves as Chair of the Executive Advisory Board of the Chemistry Life Processes Institute (Northwestern University), member of the National Council at Washington University School of Medicine, and member of the Biopharma Advisory Board at Washington University. He is member of the National Medical and Scientific Advisory Board of the Arthritis Foundation and the Lupus Research Alliance. He is also Chair of the Medical and Scientific Committee of the San Francisco Arthritis Foundation.
Dr. Chan received his B.A. and M.S. degrees in chemistry at Northwestern University and M.D. and Ph.D. degrees from Washington University (WUSM). He completed his internal medicine residency at Barnes Hospital and rheumatology fellowship at UCSF. He joined the faculty at WUSM in the Departments of Medicine and Pathology and was a member of the Howard Hughes Medical Institute. He is an elected member of the American Association of Physicians, American Society for Clinical Investigation, Henry Kunkel Society and a Pew Scholar. He is recipient of the Lee Howley Sr Prize in arthritis research, the Northwestern alumni medal, the Washington University School of Medicine Alumni Achievement award, the American Federation for Aging Research Chairman’s Award of Distinction, and the Guin Warnock Award from the Arthritis Foundation. He is also presently Associate Professor of Medicine at UCSF.
Member since 2012
Dr. Collins has been a scientific leader in the biopharmaceutical industry with 28 years of experience leading research efforts in industry to discover and develop new small molecule and protein therapeutics for the treatment of inflammatory diseases.
Dr. Collins served as Chief Scientific Officer and Vice President of the Immunology and Autoimmunity Research Unit for Pfizer in Cambridge MA from 2009 until her retirement in 2012. Prior to this, she was Vice President of Inflammation Discovery Research at Wyeth.
She currently serves on the Scientific Advisory Board of the Lupus Research Alliance and is a visiting scientist at Harvard Medical School.
Dr. Collins completed undergraduate, graduate and postdoctoral work at SUNY at Stony Brook, Wesleyan University, and the Carnegie Institute of Washington. She joined the biotechnology company Genetics Institute in 1983.
Originally trained in molecular biology and genetics, she began work in Immunology in 1987 after a sabbatical at Harvard Medical School.
Her career encompassed both the biotechnology and pharmaceutical environments due to the acquisition of Genetics Institute by Wyeth in 1996, and the acquisition of Wyeth by Pfizer in 2009.
Dr. Collins’s research interests have focused on the discovery and therapeutic application of novel pathways for modulating immune responses.
Dr. Collins is an author on over 100 scientific publications and an inventor on 35 issued US patents. She has served as a reviewer for multiple scientific journals and granting committees.
She has enjoyed collaborative interactions with scientists in the Immunology community, making scientific contributions to the field, mentoring the next generation of scientists, and contributing to improvements in healthcare.
Member since 2023
Texas A&M School of Medicine
Nancy Mize Gonzalez is an M.D./Ph.D. candidate at Texas A&M School of Medicine, in the fourth year of the program, currently in the Ph.D. phase of training. Gonzalez earned a B.A. in music from Shorter College, with First Honors summa cum laude. Originally an aspiring concert pianist, Gonzalez became deeply motivated to study biomedical science when a family member was diagnosed with pediatric lupus and autism spectrum condition.
After completing undergraduate training and working for a few years as professional choral musician, Gonzalez enrolled in post-baccalaureate science classes at the University of Alabama at Birmingham in 2016, joining the Yoder Lab to learn essential skills for hypothesis-driven research, and garnering 5 co-author publications on T cells in polycystic kidney disease as a result. In 2018, Gonzalez was accepted to the MD/PhD program at Texas A&M School of Medicine.
In Spring 2021, as a second year medical student, Gonzalez joined the Wenhao Chen lab at the Houston Methodist Research Institute, studying T cell-directed therapies in lupus models. Gonzalez’s overall research goal is to develop highly-effective therapeutics for neuropsychiatric lupus.
At Texas A&M, Nancy Gonzalez serves as Vice President for the school’s chapter of the American Association of Neurological Surgeons (AANS), and is a member of the Congress of Neurological Surgeons (CNS), Women in Neurological Surgery (WINS), and the Association of Women Surgeons (AWS). Active in the lupus community, Gonzalez is an executive member of the Lupus Research Alliance Young Leaders Board. As a professional musician, Gonzalez has sung with Coro Vocati, Peachtree Road United Methodist Chamber Choir, Music City Baroque, and has been a soprano soloist at St. Paul’s Cathedral and at the Amherst Early Music Festival. Gonzalez has earned the Robert & Annabelle Bruce Travel Grant, the Presser Foundation Scholarship, and the Alfred Shorter Competitive Academic Scholarship. After medical school, Gonzalez aspires to match to a surgical residency and work as a surgeon-scientist, staying highly engaged in translational research.
Member since 2022
Oklahoma Medical Research Foundation/Oklahoma University Health Sciences Center
Judith A. James, M.D., Ph.D., is Chair of the Arthritis and Clinical Immunology Program and holds the Lou Kerr Chair in Biomedical Research at the Oklahoma Medical Research Foundation. Dr. James is also the Associate Vice Provost for Clinical and Translational Science and Professor of Medicine and Pathology at the University of Oklahoma Health Sciences Center.
Dr. James’ research interests focus on understanding the pathogenesis, prediction, prevention and precision treatment of systemic lupus erythematosus and related disorders, the evolution and pathogenic mechanisms of autoantibodies in systemic rheumatic disease, and the interplay of genetic risk and environmental responses in systemic autoimmunity. Her work has made seminal contributions to understanding how autoimmune diseases start and the concept of humoral epitope spreading. She has published over 330 articles in journals such as the New England Journal of Medicine, Nature Medicine, Journal of Experimental Medicine, Annals of Rheumatic Disease and Arthritis and Rheumatology for example.
Dr. James currently serves as the principal investigator for several large, multi-investigator NIH-funded grants, such as the U54 Oklahoma Shared Clinical & Translational Resources from NIGMS, UM1 Autoimmunity Center of Excellence from NIAID, and P30 Rheumatic Disease Research Cores Center from NIAMS. Dr. James has conducted lectures for the American College of Rheumatology, International Systemic Lupus Erythematosus Meetings, among others.
Dr. James has received several prestigious awards including the the Stanley J. Korsmeyer award from the American Society for Clinical Investigation, the Presidential Early Career Award for Scientists and Engineers and the Dubois’ Award from the American College of Rheumatology. She has served as a member of NIAMS Council with the National Institutes of Health and as the elected Secretary-Treasurer of the American Society of Clinical Investigation. She has served on several other NIH advisory committees and chaired an NIH Roundtable regarding preclinical autoimmunity. Dr. James also was selected to provide testimony supporting the NIH at the Noel Laureates’ Hearing for the US Senate Appropriations Subcommittee.
Dr. James received her medical degree and PhD in Immunology from the Oklahoma Health Sciences Center and is a board certified adult rheumatologist. She continues to practice adult rheumatology, focusing on SLE, incomplete lupus, and related rheumatic diseases.
Member since 2023
Washington University School of Medicine
Alfred Kim, M.D., Ph.D. is an Associate Professor of Medicine at Washington University School of Medicine, where he directs the Lupus Center. He is also the Director of the Biobanking and Phenotyping Core within the NIH/NIAMS P30-funded Rheumatic Diseases Research Resource-based Center, and Faculty Scholar at the Institute of Public Health at Washington University. Additionally, he is Chief Medical Officer at Kypha, Inc.
Dr. Kim obtained his B.A. in Biochemistry from the University of Pennsylvania and his M.D. and Ph.D. from Drexel University College of Medicine. Dr. Kim did his clinical training in Internal Medicine and Rheumatology at Barnes-Jewish Hospital/Washington University School of Medicine, where he was part of the Physician-Scientist Training Program performing his post-doctoral fellowship with Dr. Andrey Shaw on the contributions of B cells in podocyte dysfunction.
Dr. Kim runs a research group that focuses on translational and clinical questions surrounding human systemic lupus erythematosus, including 1) examining the utility of complement activation products as both biomarkers of SLE disease activity and their involvement in driving disease activity in SLE, 2) testing state-of-the-art noninvasive imaging platforms such as photoacoustics to detect lupus nephritis without the need of biopsy, and 3) understanding the etiologies of health care disparities in patients with SLE and how to mitigate its negative effects on outcomes. Dr. Kim also started the COVID-19 Vaccine Responses in Patients with Autoimmune Diseases (COVaRiPAD) study, which seeks to elucidate the strength, quality, durability, evolution, and safety of COVID-19 vaccine responses in patients who take immunosuppressives for autoimmune diseases.
Dr. Kim serves on the Scientific Advisory Council at the Rheumatology Research Foundation, OMERACT SLE Working Group, Lupus Nephritis Trials Network (LNTN), Lupus Clinical Investigator Network (LuCIN), and Clinical and Scientific Committee of the COVID-19 Global Rheumatology Alliance. He is a Co-Investigator for the Lupus Research Alliance’s Lupus Nexus study. He has served on the Strategic Planning Task Force for the American College of Rheumatology, the Early Career Investigators Subcommittee within the Committee of Research of the American College of Rheumatology.
Member since 2023
Associate Professor. The Hospital for Sick Children
Dr. Andrea Knight is a pediatric rheumatologist and clinician-investigator in the Division of Rheumatology, and an Associate Scientist in the Neurosciences and Mental Health Program at The Hospital for Sick Children (SickKids) in Toronto, Canada. She is also an Associate Professor of Pediatrics at the Temerty Faculty of Medicine at the University of Toronto, and Adjunct Assistant Professor of Pediatrics in the Associated Faculty of the Perelman School of Medicine, University of Pennsylvania. She obtained her medical degree from the Columbia College of Physicians & Surgeons in New York. She then completed her Paediatric Residency and Paediatric Rheumatology Fellowship at The Children’s Hospital of Philadelphia, and a Master of Science in Clinical Epidemiology from the University of Pennsylvania.
Dr. Knight’s research program seeks to understand the impact of neuropsychiatric morbidity on outcomes for children and youth with rheumatologic disease. She is currently conducting translational research to understand the impact of childhood-onset SLE (cSLE) on brain health and development, utilizing neuroimaging, cognitive, and blood biomarkers to characterize the mechanisms underlying neuropsychiatric dysfunction. The goal is to develop and test systematic approaches utilizing multi-level biomarkers for early detection and targeted, individualized treatment of neuropsychiatric disorders in SLE. She is also developing and testing strategies to improve assessment and intervention for psychiatric morbidity, such as tailored cognitive behavioral therapy, to optimize outcomes for children and youth with rheumatologic conditions.
Dr. Knight is also leading several international research efforts in pediatric lupus and rheumatology. She is the current Chair of the Lupus Section for the Childhood Arthritis & Rheumatology Research Alliance (CARRA), and Co-leader of the CARRA Mental Health Workgroup. She is the Co-PI on a CDC-funded award to examine epidemiology and outcomes in the CARRA lupus registry cohort. She also recently served as an appointed member on the Committee for the Assessment of National Institutes of Health Research on Autoimmune Diseases (2020-2022) at the United States National Academy of Science in the department of Engineering and Medicine.
Dr. Knight’ work has been recognized by an awarded Chair for the Canada Research Tier 2 for Mental Health in Childhood Chronic Disease at the Canada Institute of Health Research. She is also the recipient of the Lupus Research Alliance Career Development Award to Promote Diversity in Lupus Research, the Lupus Foundation of America Mary Betty Stevens MD Young Investigator Prize, and the Edmond L Dubois Memorial Lectureship and Investigator Award from the Rheumatology Research Foundation.
Member since 2019
Director, Life Sciences Institute, UBC
Professor, Dept of Medical Genetics, UBC
Canada 150 Research Chair in Functional Genetics
Professor of Genetics, University of Vienna
Honorary Professor, Chinese Academy of Medical Sciences & Qingdao University
Guest Professor, Medical University of Vienna
Adjunct Professor, Dept of Immunology, University of Toronto
Josef Martin Penninger, born in Gurten, Austria, is an Austrian geneticist and the Canada 150 Research Chair in Functional Genetics. Dr. Penninger is currently the Director of the Life Sciences Institute (LSI) at the University of British Columbia. He studied medicine at the University of Innsbruck in Austria. From 1990 to 1994 he worked as post-doctoral fellow at the Ontario Cancer Institute, thereafter until 2002 at the Department of Immunology and Medical Biophysics at the University of Toronto. As Principal Investigator of Amgen, his independent lab contributed to the development of the antibody Denosumab for bone loss and also found the first connection for RANKL to mammary gland development in pregnancy and breast cancer. In 2002, he moved to Vienna, Austria to start and develop the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), which has become one of the prime research centers in the world. Dr. Penninger envisions to recreate this environment at the LSI to nurture and train the best and brightest young minds of UBC scholars. His major accomplishments include pioneering insights into the molecular basis of osteoporosis, breast cancer, and linking ACE2 and SARS or COVID-19-casing Coronavirus infections to lung failure. He has published extensively in several multidisciplinary scientific journals, with over 60 publications in Cell, Nature, and Science. Josef has received numerous awards including the Wittgenstein Prize of the Austrian Federal Government, the Descartes Prize for Research, the Ernst Jung Prize for Medical Excellence, the Innovator Award of the US Department of Defense, and most recently the Austrian Cross of Honor for Science and Art First Class. Currently he holds a Canada 150 Chair.
Member since 2019
University of Washington School of Medicine
Dr. Rawlings graduated Magna Cum Laude in Biological Sciences from Davidson College, and received his M.D. from the University of North Carolina. He completed residency and chief residency in pediatrics at UCSF, and Pediatric Rheumatology/Immunology subspecialty training at Children’s Hospital Los Angeles. He pursued post-doctoral research as an intramural fellow at the NIH and in the HHMI, UCLA. Formerly a member of the UCLA faculty, Dr. Rawlings joined the University of Washington in 2001. He directs the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute and is also chief of the Division of Immunology overseeing the immunodeficiency clinical program at Seattle Children’s Hospital. Dr. Rawlings has received numerous awards including the Seattle Children’s Guild Association Endowed Chair in Pediatric Immunology, Tom Hansen Investigator in Pediatric Innovation Endowment, and election to the American Society for Clinical Investigation and Association of American Physicians.
His primary research interests include dysregulated lymphoid development and signaling leading to immunodeficiency, autoimmunity and/or lymphoid malignancies, and the development of gene therapy for immune diseases. His laboratory uses expertise in basic and clinical immunology, signal transduction and gene editing to understand how altered signals can lead to immunologic disease, with the goal of developing translational therapies that specifically modulate key pathways.
Member since 2022
Cold Spring Harbor Laboratory
Jason Williams is Assistant Director, Inclusion and Research Readiness at the Cold Spring Harbor Laboratory DNA Learning Center where he develops national biology education programs. Jason leads education, outreach, and training for CyVerse (US national cyberinfrastructure for the life sciences) and has trained thousands of students, researchers and educators in bioinformatics, data science, and molecular biology. Jason’s focus has been developing bioinformatics in undergraduate education and career-spanning learning for biologists. Jason is founder of LifeSciTrainers.org – a global effort to promote community of practice among professionals who develop short-format training for life scientists. Jason is advisory to cyberinfrastructure, bioinformatics, and education projects and initiatives in the US, UK, Europe, and Australia. He is also a teacher at the Yeshiva University High School for Girls.